Slingshot members are tracking this event:

Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck expected April 5 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
IPHYF Community voting in process

Additional Information

Clinical Data
Enrolment began in December, 2015. As of October 11, 2016, 13 patients with R/M SCCHN were enrolled at dose levels 0.4, 1, 2 and 4 mg/kg. Median age was 60 years (range: 40-74); 92% were male; PS was 0 or 1; all patients had received prior systemic therapy (1 prior line in 1 patient and > 2
lines in 12 patients) for R/M SCCHN including platinum based chemotherapy (100% of the patients) and cetuximab (85%). There were no DLTs, infusion related reactions, immune related disorders or deaths related to treatment. No discontinuation attributable to treatment-related adverse events and no treatment-related grade 3 and 4 adverse events were reported, except fatigue (grade 3) in one patient. Updated data including pharmacodynamics and pharmacokinetics on the full dose escalation part will be presented.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 05, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Anti-nkg2a, Monalizumab, Cetuximab